Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial

There is much speculation with regard to the potential cardioprotective benefits of equol, a microbial-derived metabolite of the isoflavone daidzein, which is produced in the large intestine after soy intake in 30% of Western populations. Although cross-sectional and retrospective data support favorable associations between the equol producer (EP) phenotype and cardiometabolic health, few studies have prospectively recruited EPs to confirm this association. The aim was to determine whether the acute vascular benefits of isoflavones differ according to EP phenotype and subsequently investigate the effect of providing commercially produced S-(–)equol to non-EPs. We prospectively recruited male EPs and non-EPs (n = 14/ group) at moderate cardiovascular risk into a double-blind, placebocontrolled crossover study to examine the acute effects of soy isoflavones (80-mg aglycone equivalents) on arterial stiffness [carotid-femoral pulse-wave velocity (cfPWV)], blood pressure, endothelial function (measured by using the EndoPAT 2000; Itamar Medical), and nitric oxide at baseline (0 h) and 6 and 24 h after intake. In a separate assessment, non-EPs consumed 40 mg S-(–)equol with identical vascular measurements performed 2 h after intake. After soy intake, cfPWV significantly improved in EPs at 24 h (cfPWV change from 0 h: isoflavone, 20.2 6 0.2 m/s; placebo, 0.6 6 0.2 m/s; P , 0.01), which was significantly associated with plasma equol concentrations (R = 20.36, P = 0.01). No vascular effects were observed in EPs at 6 h or in non-EPs at any time point. Similarly, no benefit of commercially produced S-(–)equol was observed in non-EPs despite mean plasma equol concentrations reaching 3.2 mmol/L. Acute soy intake improved cfPWV in EPs, equating to an 11–12% reduced risk of cardiovascular disease if sustained. However, a single dose of commercially produced equol had no cardiovascular benefits in non-EPs. These data suggest that the EP phenotype is critical in unlocking the vascular benefits of equol in men, and long-term trials should focus on confirming the implications of EP phenotype on cardiovascular health. This trial was registered at clinicaltrials.gov as NCT01530893. Am J Clin Nutr doi: 10.3945/ajcn.115.125690.

A potential vorticity signature for the cold sector of winter extratropical cyclones

The cold sector of a midlatitude storm is characterized by distinctive features such as strong surface heat fluxes, shallow convection, convective precipitation and synoptic subsidence. In order to evaluate the contribution of processes occurring in the cold sector to the mean climate, an appropriate indicator is needed. This study describes the systematic presence of negative potential vorticity (PV) behind the cold front of extratropical storms in winter. The origin of this negative PV is analyzed using ERA-Interim data, and PV tendencies averaged over the depth of the boundary layer are evaluated. It is found that negative PV is generated by diabatic processes in the cold sector and by Ekman pumping at the low centre, whereas positive PV is generated by Ekman advection of potential temperature in the warm sector. We suggest here that negative PV at low levels can be used to identify the cold sector. A PV-based indicator is applied to estimate the respective contributions of the cold sector and the remainder of the storm to upward motion and large-scale and convective precipitation. We compare the PV-based indicator with other distinctive features that could be used as markers of the cold sector and find that potential vorticity is the best criterion when taken alone and the best when combined with any other.